This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation …

Neuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Neoplasm

~Estimated

~$50 – $1,500

Actual pay is set by the research site.

Washington University School of MedicineNCT07842172

Phase 1

211At-MABG in Adults With Advanced Neuroendocrine Cancers

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced b…

PheochromocytomaParagangliomaNeuroendocrine Tumors+3 more

~Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of PennsylvaniaNCT07661420